Abstract
Ibrutinib, a recently approved inhibitor of Bruton’s tyrosine kinase (BTK), has shown great efficacy in patients with high-risk CLL. Nevertheless, there are few data regarding its use in patients who relapsed after allogeneic stem cell transplantation (alloSCT). We report clinical data from five CLL patients treated with ibrutinib for relapse after first or even second allogeneic transplantation. Additionally, we performed analyses on cytokine levels and direct measuring of CD4 Th1 and CD4 Th2 cells to evaluate possible clinically relevant immunomodulatory effects of ibrutinib. All patients achieved partial responses including one minimal residual disease (MRD)-negative remission. Within 1 year of follow-up, no relapse was observed. One patient died of severe pneumonia while on ibrutinib treatment. Beside this, no unexpected adverse events were observed. Flow cytometry and analyses of T cell-mediated cytokine levels (IL10 and TNFα) did not reveal substantial changes in T-cell distribution in favor of a CD4 Th1 T-cell shift in our patients. No acute exacerbation of GvHD was reported. In conclusion, these results support further evaluation of ibrutinib in CLL patients relapsing after alloSCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21: 12–17.
Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 2014; 124: 3841–3849.
Cameron F, Sanford M . Ibrutinib: first global approval. Drugs 2014; 74: 263–271.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.
Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213–223.
Herman S, Gordon A, Hertlein E, Ramanunni A, Zhang X, Jaglowski S et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287–6297.
Ponader S, Chen S, Buggy J, Balakrishnan K, Gandhi V, Wierda W et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182–1190.
Herman SEM, Mustafa RZ, Jones J, Wong DH, Farooqui M, Wiestner A . Treatment with ibrutinib inhibits BTK and VLA-4 dependent adhesion of chronic lymphocytic leukemia cells in vivo. Clin Cancer Res 2015; 21: 4642–4651.
Ansell S . Two targets for the price of one. Blood 2013; 122: 2529–2531.
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122: 2539–2550.
Nishimori H, Maeda Y, Tanimoto M . Chronic graft-versus-host disease: disease biology and novel therapeutic strategies. Acta Med Okayama 2013; 67: 1–8.
Yeh S-P, Liao Y-M, Lo W-J, Lin C-L, Bai L-Y, Lin C-Y et al. Kinetics of T helper subsets and associated cytokines correlate well with the clinical activity of graft-versus-host disease. PLoS ONE 2012; 7: e44416.
Hayashida J-N, Nakamura S, Toyoshima T, Moriyama M, Sasaki M, Kawamura E et al. Possible involvement of cytokines, chemokines and chemokine receptors in the initiation and progression of chronic GVHD. Bone Marrow Transplant 2013; 48: 115–123.
Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009; 114: 3101–3113.
Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia. Blood 2008; 111: 5446–5457.
Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O’Brien S et al. Outcomes of patients with chronic lymphocytic leukemia and Richter’s transformation after transplantation failure. J Clin Oncol 2015; 33: 1557–1563.
Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S et al. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. Br J Haematol 2013; 160: 640–648.
Hahn M, Böttcher S, Dietrich S, Hegenbart U, Rieger M, Stadtherr P et al. Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse. Bone Marrow Transplant 2015; 50: 1279–1285.
Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi et al. Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk 2014; 14: e105–e109.
Toze CL, Dalal CB, Nevill TJ, Gillan TL, Abou Mourad YR, Barnett MJ et al. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Br J Haematol 2012; 158: 174–185.
Coutre S, O’Brien S, Byrd J, Hillmen P, Brown J, Dyer M et al. Safety and efficacy of ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have undergone prior allogeneic stem cell transplant. Blood 2014; 124: 4697.
Miklos DB, Coutre S, O’Brien S, Byrd JC, Hillmen P, Brown JR et al. Safety and efficacy of ibrutinib in patients with relapsedrefractory (RR) chronic lymphocytic leukemia (CLL)-small lymphocytic lymphoma (SLL) who have undergone prior allogeneic stem cell transplant. Biol Blood Marrow Transplant 2015; 21: S82–S83.
Montserrat E, Dreger P . Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation. J Clin Oncol 2015; 33: 1527–1529.
Ryan CE, Logan AC, Rezvani A, Kamdar M, Nakasone H, Sahaf B et al. Ibrutinib treatment of relapsed CLL following allogeneic transplantation-sustained disease response and promising donor immune modulation. Blood 2014; 124: 1186.
Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747–2753.
Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 2013; 27: 362–369.
De Jong J, Skee D, Murphy J, Sukbuntherng J, Hellemans P, Smit J et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect 2015; 3: e00156.
Allen J, Tata P, Fore M, Wooten J, Rudra S, Deal et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood 2014; 123: 2108–2116.
Sarantopoulos S, Ritz J . Aberrant B-cell homeostasis in chronic GVHD. Blood 2015; 125: 1703–1707.
Dubovsky J, Flynn R, Du J, Harrington B, Zhong Y, Kaffenberger B et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 2014; 124: 4867–4876.
Schutt SD, Fu J, Nguyen H, Bastian D, Heinrichs J, Wu Y et al. Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice. PLoS ONE 2015; 10: e0137641.
Miklos DB, Arora M, Cutler CS, Nakamura R, Juretic M, Li Y et al. A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease (cGVHD). J Clin Oncol 2015; 33: 7024.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JS has a conflict of interest; he gives a talk for Janssen Pharmaceutical Company.
Additional information
Supplementary Information accompanies this paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Link, C., Teipel, R., Heidenreich, F. et al. Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation. Bone Marrow Transplant 51, 793–798 (2016). https://doi.org/10.1038/bmt.2015.339
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.339
This article is cited by
-
Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience
Annals of Hematology (2019)
-
Ibrutinib
Reactions Weekly (2018)
-
Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation (2017)
-
Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
Drugs & Aging (2017)
-
Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation (2017)